

Enrollment

**Assessed for eligibility
(n = 1262)**

Excluded (n = 49)

- Chronic illness (n = 12)
- Lab abnormalities (n = 27)
- Taking concomitant medications (n = 7)
- Other (n = 3)

Allocation

**Randomised
(n = 1213)**

Randomised to other interventions (n = 389)

- Fluoxetine (n = 120)
- Ensitrelvir (n = 95)
- Tixagevimab/cilgavimab (n = 96)
- Ritonavir-boosted nirmatrelvir + Molnupiravir (n = 44)
- Nitazoxanide (n = 34)

Analysis

**ITT in included drug arms
(n = 824)**

Excluded from analysis (n = 24)

- Non-compliance with study procedures prior to day 2 (n = 8)
 - Withdrawn as given rescue medications (n = 2)
 - Withdrawn due to side-effects (n = 2)
 - Withdrew consent for other reasons (n = 4)
- Withdrew consent before starting interventions (n = 11)
- Undetectable viral loads (n = 5)

Analysed dataset; mITT (n = 800)

- No study drug (n = 263)
- Ritonavir-boosted nirmatrelvir (n = 158)
- Favipiravir (n = 114)
- Casirivimab/imdevimab (n = 88)
- Remdesivir (n = 67)
- Molnupiravir (n = 66)
- Ivermectin (n = 44)